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Abstract
Introduction: Renal cell carcinoma with the distinct type of t(6;11)(p21;q12) translocation (transcription factor EB)
is a rare neoplasm. In the present case study, we show for the first time an autophagy signature in a patient with
transcription factor EB renal cell carcinoma. We attempted to characterize the mutational and expressional features
of a t(6;11)(p21;q12) renal cell carcinoma, in an effort to address the potential for molecular guidance of personalized
medical decision for a case in this renal cell carcinoma category.
Case presentation: We report the case of a 42-year-old white man who had a late relapse of his renal cell carcinoma.
The first diagnosis of clear cell renal carcinoma was derived from a histological examination; analyzing the metastasis
and going back to the primary tumor it turned out to be a transcription factor EB-renal cell carcinoma. The treatment
plan included local radiation and systemic therapy. As part of the multimodal approach, tumor samples for genetic
assessment were obtained. However, there is no recommended standard therapy for transcription factor EB-renal cell
carcinoma. Despite four lines of medical treatment with targeted therapy and one checkpoint inhibitor, all attempts to
prolong the patient’s survival failed.
Conclusions: During the course of this unusual disease, we gained insights which, to the best of our knowledge, were
unknown before in the expression of the gene signature linked to autophagy. This might in part explain the resistance
to conventional targeted therapy acknowledged in our patient.
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Introduction
The translocation involves on chromosome 6 the MITF
transcription factor family member transcription factor
EB (TFEB), and on chromosome 11 the metastasis-
associated lung adenocarcinoma transcript 1 (MALAT1).
It has previously been shown that the TFEB transcription
factor is involved in the regulation of autophagy (see [1]
for a review of the role of TFEB in this setting). Sardiello
et al. defined an autophagy gene network regulating
lysosomal biogenesis and function through a systematic
study of TFEB upregulation [2]. Indirectly, these features
can be observed immunohistochemically when tumor
cells express cathepsin K in the cytoplasm [3]. This is a
consequence of the dysregulation induced by the trans-
location, as TFEB controls cathepsin K expression. TFEB
protein is highly expressed in osteoclasts and TFEB is
linked to RANKL activity [4].
Among the published cases of this pathologic trans-
location variant, it appears that the therapeutic targets
against common renal cell carcinoma (RCC) may not be
effective against translocation type RCC, possibly due to
distinct molecular alterations of these carcinomas [5].
Case presentation
A 42-year-old white man had a history of kidney cancer
from 2005. At that time, his right kidney was removed,
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and RCC was concluded on the basis of histology. The
disease was staged as T3apN0M0 (TNM-Union for
International Cancer Control, TNM-UICC, 2010). The
cancer was regarded as localized and no further investi-
gation was undertaken at the time. In the winter of
2013, the patient consulted his general practitioner for
increasing right-sided lateral chest pain. Computed tom-
ography (CT) of his thorax revealed a lateral mass
destructing his third rib, without penetrating through
the pleural cavity. Several biopsies were obtained and
the tumor was confirmed as clear cell RCC. However,
the pathologist responsible had doubts about the correct
histology and consulted experts in the field for a second
opinion abroad. Techniques including Sanger sequencing
of the candidate translocation region and fluorescence in
situ hybridization (FISH) confirmed a translocation in-
cluding TFEB (t6;11), which is diagnostic of RCC. Im-
munohistochemistry was positive for cathepsin K and
Melan-A, which supported the diagnosis.
Further investigation of the patient with magnetic res-
onance imaging (MRI; Fig. 1) of his vertebral column
showed small lesions in his lower lumbar spine, suspi-
cious of tumor spreading to his skeleton. This clinical
picture, and the first immunohistochemical results
showing intensive staining of cathepsin K, pointed to
dysfunctional activity in osteoclasts, and linked thera-
peutic choices to autophagy and metabolism. He was re-
ferred to surgical resection of the part of his chest wall
afflicted by a tumor mass, which was conducted at the
University Hospital Oslo in September 2013. Postopera-
tively, he received irradiation to the tumor bed, 3 Gy per
fraction to a total dose of 30 Gy.
Today, there is no commonly accepted treatment rec-
ommendation for non-RCC. Pending the final histology
report, while having the clinicopathological suspicion of
translocational RCC, several therapeutical strategies were
discussed. In the light of no available standard treatment
for patients with translocational RCC, a mammalian target
of rapamycin (mTOR) inhibitor (everolimus 10 mg daily)
counteracting phosphorylation of TFEB by mTOR com-
plex 1 (mTORC1) [6] and denosumab (120 mg subcutane-
ously every fourth week), a monoclonal antibody
regulating osteoclast activity by targeting the RANK lig-
and, were both applied during and after postsurgical
radiotherapy. This therapeutic strategy aimed to counter-
act the dysfunctional signaling effect in catabolism and
bone reabsorption as described for TFEB tumors. In
addition, the formerly nephrectomized patient had moder-
ately reduced kidney function after the operation, and
needed self-catheterization. Often tyrosine kinase inhibi-
tors (TKIs) affect kidney function, supporting an mTOR
pharmacological treatment instead of TKI for this patient.
Unfortunately, everolimus led to thrombocytopenia and
had to be reduced to 7.5 mg per day taken orally. During
the next 2 months, the patient’s health deteriorated, and
the mTOR-inhibitor therapy was eventually interrupted.
A new series of MRI (Fig. 1) confirmed progression,
with multiple additional bony lesions. The patient was
treated with a broadly acting TKI, pazopanib (800 mg
once daily) as second-line medical treatment, interfering
with platelet-derived growth factor (PDGF) and vascular
endothelial growth factor (VEGF) pathways. At the same
time, neither anti-1-amino-3-18F-fluorocyclobutane-1-
carboxylic acid (18F-FACBC) positron emission tomog-
raphy (PET)/CT nor 2-deoxy-2-(18F)fluoro-D-glucose
(18F-FDG) PET/CT scans detected tumor spreading.
Acknowledging the difficulty in identifying a rational
therapeutic approach, the patient consented to serial bi-
opsies taken in February and June 2014, preceding the
choice of a new treatment due to a major lesion in his
sacrum. Both samples were then assessed molecularly by
Agilent SureSelect exome capture with Illumina sequen-
cing, and expression profiling using bead arrays from
Illumina.
Ribonucleic acid (RNA) extraction from the tumor
taken at the first time point was split in two parts and a
TissueLyser (Qiagen) was used to disrupt the sample.
RNA from both parts was extracted using a GenElute
Fig. 1 Magnetic resonance imaging visualizing metastatic spine lesion (arrow)
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Mammalian Total RNA Miniprep Kit (Sigma-Aldrich),
according to the manufacturer’s instructions. DNA was
extracted from the tumor taken at the second time point,
using the NucleoSpin Tissue Kit (Macherey-Nagel), ac-
cording to the manufacturer’s protocol. Normal DNA was
extracted from ethylenediaminetetraacetic acid (EDTA)
blood using the NucleoSpin Blood Midi Kit (Macherey-
Nagel), according to the manufacturer’s protocol. Normal
and tumor DNA was subjected to whole exome sequen-
cing using the SureSelect whole exome v5 and Illumina
sequencing by synthesis technology (HiSeq 2500) follow-
ing the supplier’s protocol. The resulting FASTQ files
were further analyzed using an in-house developed pipe-
line for somatic event detection. Reads of the tumor and
its matched control sample were separately mapped with
BWA-MEM [7] to human reference genome (build b37)
with an added decoy contig, obtained from [8]. Sample-
wise sorting and duplicate marking was performed on the
initial alignments with Picard tools [9]. Genome Analysis
Toolkit (GATK) tools [10] were subsequently used for
two-step local realignment around indels (in this step,
both samples were processed together). Each sample’s
pair-end read information was then checked for inconsist-
encies with Picard, and base-quality recalibration was per-
formed by GATK.
Somatic variant calling on the sample pair was done
with MuTect [11] (somatic single nucleotide variant,
SNV, detection), Strelka [12] (somatic SNV and INDEL
detection), DELLY [13] (large-scale variation – deletions,
duplications, translocations and inversions – detection)
and VarScan2 [14] (somatic copy number variation,
CNV, analysis).
GATK tools were used for computing coverage statis-
tics based on the recalibrated alignment files.
Most of the analysis (starting with the local realignment
step) was limited to exome regions, defined by Agilent se-
quencing probes (for further details, see Additional file 1).
One translocation was identified through sequencing,
involving positions chr11:65,267,772 and chr6:41,659,234,
involving the expected TFEB translocation previously de-
scribed for this patient.
We identified 23 somatic single SNVs, and three inser-
tion/deletion events. Among these, one mutated gene was
located in the tumor necrosis factor (TNF) receptor path-
way (MAP3K7, G110V), a pathway previously implicated
in clear cell RCC [15]. However, no obvious candidate
therapeutic target genes were identified as mutated.
A DNA copy number plot is shown in Fig. 2. Gain of a
region of 1q including the gene KIF14 has previously
been associated with fatal progression, and KIF14 was
among the genes reported to be overexpressed in tumors
with 1q [16]. We did identify a somatic mutation for this
gene (H849Y), but the tumorigenic potential remains
unclear. Other chromosome arm scale events with more
or less clear breaks could be seen on chromosomes 1, 3,
18 and 22. Some chromosomes (9, 13, 19) appeared to
be generally underrepresented by sequencing reads in
the tumor, while some other chromosomes (for example
2 and 7) seemed to be affected by many smaller events.
Transcriptome analysis was performed using the TruSeq
Stranded Total RNA with Ribo-Zero Gold from Illumina
according to the manufacturer’s instructions. The RNAa-
Seq library was sequenced using a HiSeq 2500 with a
paired-end 2×100 base pair (bp) approach. The sequencing
reads were mapped with TopHat2 [17] to human reference
genome/transcriptome (build hg19) and subsequently
processed by the Cufflinks2 tools [18] (cufflinks, cuffmerge,
cuffdiff) in order to generate a gene-wise fragments per
kilobase of transcript per million mapped reads (FPKM)
expression (Table 1).
A plot of normalized transcript counts is shown in
Fig. 3a. In order to estimate upregulation of transcrip-
tion compared to a normal kidney, we obtained tran-
script counts from the RNA-Seq Atlas [19] (Fig. 3b). In
order to evaluate whether there was an expression effect
of TFEB being overexpressed, we examined whether
genes that previously had been reported as upregulated
in transiently TFEB-overexpressed HeLa cells were also
affected in the tumor (Fig. 3a, TFEB curve). A marked
curve shift towards higher transcript levels, compared to
the full list of genes, was observed, indicating that the
high TFEB level observed in the tumor also increased
expression of the reported target genes. We also exam-
ined whether a previously reported gene set for coordi-
nated lysosomal expression and regulation (CLEAR) was
upregulated in the tumor, and this could also be ob-
served. Moreover, TFEB expression is very high in the
tumor, compared to TFEB expression levels observed
otherwise in normal kidney tissues [20, 21].
The transcriptional profile confirmed the clinical sus-
picion of highly upregulated macro-autophagy and dys-
functional pathway activity in c-MET, MAPK, TSC2 and
S100A9, and downregulation of mTOR, as previously re-
ported relevant for this type of tumor (Fig. 3). Treatment
with an autophagy-inhibiting agent, hydrochloroquine
200 mg twice a day, was therefore started and subse-
quently increased to 400 mg twice a day, but stopped
when progression was observed in July 2014.
Unfortunately, 5 months after the start of pazopanib,
the CT and MRI evaluation confirmed progression, and
the treatment was switched to another broad-acting TKI,
sunitinib dose 37.5 mg per day, as third-line therapy.
In the wake of the genetic results and the approval of
checkpoint inhibitor therapy, a second course of palliative
radiotherapy was planned in late July 2014 (see Fig. 4).
The second biopsy results gained from DNA pointed
to enhanced autophagy gene signature and MAPK and
AKT pathways downstream. On histological examination,
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cathepsin K and Melan-A were highly positive. Due to
local pain in the patient’s chest wall, a second course of
three-dimensional CT conformal radiotherapy encompass-
ing pleural metastases (3 Gy per fraction, 5 days per week)
was planned 4 weeks later, and sunitinib treatment
was halted prior to radiotherapy. Acute pleural bleeding
confirmed with a CT scan showed tumor growth after 8
fractions of radiotherapy, and further irradiation was
abolished. Sunitinib treatment was discontinued.
In view of the young age of the patient and the specific
staining for Melan-A expressing tumor cells [22] (Fig. 5),
he was finally accepted for ipilimumab, targeting CTLA-
4, activating the immune system, combined with third-
line sorafenib treatment, a kinase inhibitor used in the
treatment of renal cancer. Ipilimumab was withdrawn
rapidly, due to controversies around combined treat-
ment in the physicians group, exaggerated by temporary
health deterioration of the patient. At last follow-up, 16
months after the diagnosis of translocational RCC, the
patient’s sorafenib treatment stopped due to disease pro-
gression and he died shortly afterwards.
Attempts of cell culture of excess cell material from
the bone biopsy in medium were unsuccessful.
Discussion
A subclass of renal tumors, translocation renal tumors,
involves somatic translocations of transcription factors
that are members of the MITF family, essentially deregu-
lating gene expression control. Translocations involving
the TFEB are less common than transcription factor E3
(TFE3), with only 30 confirmed cases reported in the lit-
erature [23]. Here we describe the therapeutic despair
which comes along when treating such a fatal cancer,
and an attempt to apply molecular guidance for treat-
ment of this disease. To the best of our knowledge, it is
the first such study of the clinical course of TFEB RCC
combined with genetic elucidation in a young man with
metastatic disease. There is a paucity of comprehensive
reports on the clinicogenetic findings in translocation-
driven RCC, but recently the clinicopathological mani-
festations in TFEB have been acknowledged, contribut-
ing to the correct diagnosis [23]. The sequencing-based
approaches added some important clues to the under-
standing of this entity in our patient, primarily from ex-
pression profiling, as a few mutations that can potentially
serve as a drug target could be identified. The main find-
ing in our case was the upregulated activity in autophagy.
Fig. 2 Copy number analysis by chromosome (using VarScan2/DNAcopy)
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Dysfunctional autophagy activity guided us in our search
for interpretation of the results showing activity in genes
and transcript expression in self-destruction [24, 25]. The
TFEB gene mutation correlated clinically with prolifera-
tion and invasion of bony structures, liver and pleural
manifestations. The tumor exhibited an extremely aggres-
sive clinical behavior during radiotherapy and was non-
responsive to mTOR inhibitor, and moreover showed only
modest response to a variety of medical interventions and
TKIs. In addition, patients with von Hippel–Lindau
(VHL) syndrome can develop clear cell RCC and a sub-
group of such patients may have similarities with those
described in the transcriptome of our study [26].
The role of MITF family transcription factors in renal
cell transformation to mutant cancer cell has yet to be
elucidated in depth. However, the transcription of TFEB
is acknowledged as the master regulator of the mTOR
nutrients sensing machinery, in a hypoxia-inducible
transcription factor (HIF) independent manner [27]. The
intriguing overlap between the more common phenotype
of RCC to translocation-driven RCC constitutes the meta-
bolic disarrangement leading to dysfunctional activity in
these cells and, as we propose in our case, to uncontrolled
autophagy.
In our data, the TFEB driver mutation favored en-
hanced osteoclast activity, and upregulated cathepsin K
was confirmed in several biopsies, and promoting a gene
signature connected to MAPK and c-MET signal path-
ways. It is known that TFEB, the master regulator of
lysosome biogenesis, controls transcription of target
genes closely related to lysosomal structure and func-
tion, including hydrolases. Our findings in the DNA
motif demonstrated upregulation of genes previously
reported to be induced in cells where TFEB was over-
expressed. The same signature overlapped with the
CLEAR motif in RNA samples. Tsuda et al. showed
recently that mTORC1 is a key upstream kinase that
directly phosphorylates TFEB and inhibits its activity
[28]. In addition, nuclear TFEB translocation may re-
establish autophagy, enforcing metabolic activity in cancer
Table 1 Somatic mutations detected in tumor
Variant ID Vartype Gene Consequence Coding change Depth
tumor
AF tumor Depth
normal
chr1_200567369_G_A snv KIF14 missense_variant p.H849Y 225 0.227 99
chr1_235909689_G_GCC INdel LYST frameshift_variant&feature_elongation p.A2640fs 575 0.177 255
chr1_43239249_C_T snv C1orf50 stop_gained p.R71X 330 0.352 296
chr10_124897147_G_T snv HMX3 missense_variant p.G325V 252 0.286 189
chr10_48388199_C_T snv RBP3 missense_variant p.M893I 253 0.229 149
chr12_31238059_A_G snv DDX11 missense_variant p.R213G 32 0.188 16
chr14_57858330_G_A snv NAA30 missense_variant p.E219K 165 0.212 94
chr14_57858331_A_T snv NAA30 missense_variant p.E219V 165 0.218 94
chr17_28887148_T_A snv TBC1D29 missense_variant p.L9Q 140 0.05 89
chr17_7256853_G_A snv KCTD11 missense_variant p.E198K 167 0.192 132
chr18_14542791_C_T snv POTEC missense_variant p.A119T 84 0.083 47
chr19_35842950_G_A snv FFAR1 missense_variant p.G166S 564 0.278 358
chr2_202492837_T_A snv TMEM237 missense_variant p.N302I 191 0.215 90
chr20_23065590_C_G snv CD93 missense_variant p.G414R 410 0.21 230
chr21_45535623_C_A snv PWP2 missense_variant p.P220T 130 0.208 96
chr3_108348015_A_G snv DZIP3 missense_variant p.T230A 114 0.272 45
chr4_110885598_C_T snv EGF stop_gained p.R494X 402 0.274 260
chr4_155298451_T_A snv DCHS2 missense_variant p.E127V 225 0.164 113
chr5_178771091_C_A snv ADAMTS2 missense_variant p.V71L 333 0.258 194
chr5_65105904_TC_T inDEL NLN frameshift_variant&feature_truncation p.Q586fs 333 0.168 200
chr6_136589425_G_T snv BCLAF1 missense_variant p.P758T 123 0.089 35
chr6_33406615_C_G snv SYNGAP1 missense_variant p.T532R 345 0.22 241
chr6_91271355_C_A snv MAP3K7 missense_variant p.G110V 558 0.246 305
chr7_143096972_G_T snv EPHA1 missense_variant p.R203S 222 0.212 153
chr9_139571036_C_T snv AGPAT2 splice_donor_variant exon5:c.588 + 1G > A 83 0.337 103
snv single nucleotide variant; INdel insertion of the deletion of the bases
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cells normally seen in periods of starvation conducted by
the autophagy program. Again, the gene signature showed
increased expression of autophagy-related genes, support-
ing our assumption.
Second, in our search for involved signaling pathways
and oncologic drivers, we found that c-MET RNA was
increased in our obtained biopsies. Our patient had bone
lesions early in the course of his metastatic disease,
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Fig. 3 Density plots showing the distributions of ribonucleic acid expression levels for all genes detected in the tumor (black curve; a) and the
RNA-Seq Atlas (b). Two subsets of genes are also shown: the blue curve demonstrates the genes previously reported to be induced in cells where
transcription factor EB is transiently overexpressed, and the red curve illustrates the coordinated lysosomal expression and regulation motif
(GTCACGTGAC) which overlaps the E-box motif (CANNTG) to which transcription factor EB also binds. The x-values represent the log 2 values of
fragments per kilobase of transcript per million mapped reads. Also shown are specific expression levels for genes discussed in the text. PMEL was
not found in the RNA-Seq Atlas. The y-values for these genes bear no meaning, other than to avoid overlap of names
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which is in line with the c-MET hyperactivity seen in
germline mutations of hereditary papillary RCC and bone
metastases of RCC. Moreover, patients with upregulation
of lysosomes in osteoclasts might benefit from c-MET in-
hibitors, such as cabozantinib, where the c-MET signal
pathway is stimulated by TFEB to trigger lysosomal acid-
ification and degradation of the extracellular bone micro-
environment supporting the activity of osteoclasts [29]. In
our case, the metastasis stemmed from the rib, and the
first signs of disseminated spread were localized to the
spine. We tried to counteract the possibility of tumor-
related autophagy with hydrochloroquine. This was an un-
proven experimental off-label approach, but has been tried
in other solid tumors before. Unfortunately, we did not
have access to c-MET inhibitors, which would have been
a more targeted attempt supported by the gene expression
findings from the biopsies.
Some interesting similarities, but also striking differ-
ences, to clear cell RCC were seen. In clear cell RCC,
mutations in the VHL gene lead to upregulation of
mTOR and glycolysis. In TFEB RCC, mechanisms differ-
ent from aerobic glycolysis may be active. One possible
major difference is the involvement of c-MYC, which
has been linked to HIF-1 metabolism and glutaminolysis
[30]. One other interesting feature in our patient with
autophagy addiction points to the use of the amino acid
arginine, and an increased arginase activity was seen,
which also could be clinically exploited. The often re-
lated metabolic shift in energy rescue seen in clear cell
RCC was not apparent in our case. This may have con-
sequences for imaging, in that 18F-FDG PET may not be
suitable to detect disease activity. Previously, baseline
high 18F-FDG PET uptake and increased number of
positive lesions have been associated with prognostic in-
formation in patients receiving sunitinib [31]. As seen in
our patient, the hybrid PET/CT combined with 18F-FDG
or 18F-FACBC as radiotracers could not convey valuable
information about the location or activity of metastases.
However, the possible addiction for glutamine and/or ar-
ginine and possible dysfunctional metabolism should be
tested with novel amino acid radiotracers in these pa-
tients. In the wake of specific TFEB RCC radiotracers, it
seems that the first choice of standard radiological diag-
nosis in this tumor is MRI. MRI assessment conceived
bone and soft tissue lesions and was reliable to address
the efficacy of target therapy.
Fig. 4 The course of treatment
Fig. 5 a Primary tumor with positive Melan-A staining. b Metastasis with positive Melan-A staining
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Conclusions
The clinical features with initially osteolytic bony lesions
in our patient, together with the recognized autophagic
genetic fingerprint supervised our therapeutic approach,
representing a first step into precision medicine for this
patient group.
The efficacy of TKIs and mTOR inhibitors appears lim-
ited in translocational RCC. Treatment duration in those
patients may last when intrinsic patterns of resistance to a
particular agent could be obtained. To do so, serial biopsies
of metastatic lesions were sampled in our patient. We
found a clear molecular link to activated autophagy and
osteoclast enhancement, but poor response to existing tar-
geted therapy. Of note, a possible durable effect by ipilimu-
mab in combination with a TKI presumably stimulating
the immune system and this observation deserves further
investigation. Despite the limited therapeutic benefits
achieved in our case, clarifying the essential genetic make-
up may portend the future treatment in this rare disease.
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